Search Result

Results for "

demethylase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Histone Demethylase (104) Antibiotic (4) Apoptosis (19) Autophagy (5) Bacterial (6) CD38 (1) CFTR (2) CMV (1) Cytochrome P450 (9) DNA/RNA Synthesis (2) Dopamine Receptor (3) Dopamine β-hydroxylase (1) Endogenous Metabolite (8) Estrogen Receptor/ERR (1) Fat Mass and Obesity-associated Protein (FTO) (3) Ferroportin (1) Fungal (18) HDAC (5) Hedgehog (4) Histone Methyltransferase (2) HSV (1) MDM-2/p53 (1) Mitochondrial Metabolism (4) MMP (1) Monoamine Oxidase (13) PROTACs (1) TGF-beta/Smad (1) TNF Receptor (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (116) Cardiovascular Disease (6) Infection (21) Inflammation/Immunology (6) Metabolic Disease (4) Neurological Disease (10)

By Targets:

Histone Demethylase (104)

Antibiotic (4)

Apoptosis (19)

Autophagy (5)

Bacterial (6)

CD38 (1)

CFTR (2)

CMV (1)

Cytochrome P450 (9)

DNA/RNA Synthesis (2)

Dopamine Receptor (3)

Dopamine β-hydroxylase (1)

Endogenous Metabolite (8)

Estrogen Receptor/ERR (1)

Fat Mass and Obesity-associated Protein (FTO) (3)

Ferroportin (1)

Fungal (18)

HDAC (5)

Hedgehog (4)

Histone Methyltransferase (2)

HSV (1)

MDM-2/p53 (1)

Mitochondrial Metabolism (4)

MMP (1)

Monoamine Oxidase (13)

PROTACs (1)

TGF-beta/Smad (1)

TNF Receptor (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (116)

Cardiovascular Disease (6)

Infection (21)

Inflammation/Immunology (6)

Metabolic Disease (4)

Neurological Disease (10)

156

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

FB23 1 Publications Verification	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FB23 is a potent and selective FTO demethylase inhibitor with an IC₅₀ of 60 nM. FB23 directly binds to FTO and selectively inhibits FTO's mRNA N ⁶-methyladenosine (m6A) demethylase activity .

INCB059872	Histone Demethylase	Cancer
INCB059872 is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 can be used for the research of myeloid leukemia .

INCB059872 dihydrochloride	Histone Demethylase	Cancer
INCB059872 dihydrochloride is a potent, orally active, selective and irreversible Lysine-Specific Demethylase 1 (LSD1) inhibitor. INCB059872 dihydrochloride can be used for the research of myeloid leukemia .

*14α-Demethylase/DNA Gyrase-IN-2*	Bacterial DNA/RNA Synthesis	Infection
14α-Demethylase/DNA Gyrase-IN-2 (Compound 6a) is a potent inhibitor of *14α-Demethylase/DNA* Gyrase. 14α-Demethylase/DNA Gyrase-IN-2 has antimicrobial activities .

*14α-Demethylase/DNA Gyrase-IN-1*	Bacterial DNA/RNA Synthesis	Infection
14α-Demethylase/DNA Gyrase-IN-1 (Compound 7c) is a potent inhibitor of *14α-Demethylase/DNA* Gyrase. 14α-Demethylase/DNA Gyrase-IN-1 has antimicrobial activities .

Arasertaconazole	Cytochrome P450 Bacterial Fungal	Infection
Arasertaconazole is a potent 14α-lanosterol demethylase inhibitor. Arasertaconazole has antifungal and antibacterial activity .

E67-2	Histone Methyltransferase	Cancer
E67-2, as the E67 derivative, is a low-toxicity, selective KIAA1718 Jumonji domain inhibitor with an IC₅₀ value of 3.4 µM. E67-2 selectively inhibits histone H3 lysine 9 (H3K9) Jumonji demethylase as well as histone H3 lysine 4 (H3K4) demethylase .

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of *lysine-specific demethylase* 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i** values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible *Lysine-specific demethylase* 1 (LSD1)** inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research .

Daminozide 2 Publications Verification	Histone Demethylase	Cancer
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

Daminozide (Standard)	Histone Demethylase	Cancer
Daminozide (Standard) is the analytical standard of Daminozide. This product is intended for research and analytical applications. Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC50s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

Senecionine Senecionan-11,16-dione, 12-hydroxy-; Aureine; Senecionin	Others	Metabolic Disease
Senecionine (Senecionan-11,16-dione, 12-hydroxy-) is a pyrrolizidine alkaloid could be isolated from Senecio vulgaris. Senecionine decreases the activities of glutathione S-transferase, aminopyrine demethylase and arylhydrocarbon hydroxylase (AHH) .

MO-I-500	Others	Cancer
MO-I-500 is a pharmacological of FTO inhibitor with an IC₅₀ of 8.7 μM for the inhibition of purified FTO demethylase catalyzing demethylation of an artificial small methylated substrate. MO-I-500 can be used for the research of rare panresistant triple-negative inflammatory breast cancer .

PFI-90	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

FTO-IN-8	Fat Mass and Obesity-associated Protein (FTO)	Cancer
FTO-IN-8 (FTO-43) is a N6-methyladenosine demethylase (FTO) (fat mass- and obesity-associated protein) inhibitor with the IC₅₀ value of 5.5 μM. FTO-IN-8 has anti-cancer cell proliferative activity .

LSD1-IN-21	Histone Demethylase TNF Receptor	Inflammation/Immunology Cancer
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated LSD1 (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .

2,4-PDCA	Histone Demethylase	Cancer
2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including *JmjC domain-containing family of histone demethylases* (JHDMs)**. 2,4-PDCA is a target chemical in the field of bio-based plastics .

GSK-J4 hydrochloride Maximum Cited Publications 37 Publications Verification	Histone Demethylase	Cancer
GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK-J4 hydrochloride is a cell permeable proagent of GSK-J1 .

FB23-2 10+ Cited Publications	Apoptosis	Cancer
FB23-2 is a potent and selective inhibitor of mRNA N ⁶-methyladenosine (m ⁶A) demethylase FTO, with an IC₅₀ of 2.6 μM. FB23-2 has anti-proliferation activity. FB23-2 can be used for the research of acute myeloid leukemia (AML) .

Senecionine (Standard)	Others	Metabolic Disease
Senecionine (Standard) is the analytical standard of Senecionine. This product is intended for research and analytical applications. Senecionine (Senecionan-11,16-dione, 12-hydroxy-) is a pyrrolizidine alkaloid could be isolated from Senecio vulgaris. Senecionine decreases the activities of glutathione S-transferase, aminopyrine demethylase and arylhydrocarbon hydroxylase (AHH) .

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit histone demethylases and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

KDM5B-IN-3	Histone Demethylase	Cancer
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC₅₀ of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer .

GSK-J4 Maximum Cited Publications 37 Publications Verification	Histone Demethylase Apoptosis	Cancer
GSK-J4 is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC₅₀s of 8.6 and 6.6 μM, respectively. GSK-J4 inhibits LPS-induced TNF-α production in human primary macrophages with an IC₅₀ of 9 μM. GSK J4 is a cell permeable proagent of GSK-J1 . GSK-J4 induces endoplasmic reticulum stress-related apoptosis .

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of *lysine specific demethylase* 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC₅₀** value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

Bomedemstat IMG-7289	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

Bomedemstat hydrochloride IMG-7289 hydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) hydrochloride is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat hydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat hydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

Bomedemstat dihydrochloride IMG-7289 dihydrochloride	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) dihydrochloride is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat dihydrochloride can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat dihydrochloride shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

Fenoldopam mesylate 4 Publications Verification Fenoldopam methanesulfonate; SKF-82526 mesylate	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam mesylate (SKF-82526) is a D₁ receptor agonist and a novel *lysine-specific demethylase* 1 (LSD1) inhibitor (IC₅₀**=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

Bomedemstat ditosylate IMG-7289 ditosylate	Histone Demethylase Apoptosis	Cancer
Bomedemstat (IMG-7289) ditosylate is an orally active and irreversible *lysine-specific demethylase* 1 (LSD1**) inhibitor. Bomedemstat ditosylate can increase H3K4 and H3K9 methylation, and then alter gene expression. Bomedemstat ditosylate shows anti-cancer activities, inhibits cancer cell proliferation and induces apoptosis .

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase* 1(LSD1)/Histone deacetylase 6 (HDAC6)**, with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

FTO-IN-10	Fat Mass and Obesity-associated Protein (FTO) Autophagy	Metabolic Disease
FTO-IN-10 (compound 7) is a potent human demethylase FTO (the fat mass and obesity-associated protein) inhibitor with an IC₅₀ of 4.5 μM. FTO-IN-10 enters the FTO’s structural domain II binding pocket through hydrophobic and hydrogen bonding interactions. FTO-IN-10 induces DNA damage and autophagic cell death in A549 cells .

Fenoldopam mesylate (Standard)	Dopamine Receptor Apoptosis	Cardiovascular Disease Cancer
Fenoldopam (mesylate) (Standard) is the analytical standard of Fenoldopam (mesylate). This product is intended for research and analytical applications. Fenoldopam mesylate (SKF-82526) is a D1 receptor agonist and a novel lysine-specific demethylase 1 (LSD1) inhibitor (IC50=0.8974 μM). Fenoldopam mesylate shows anti-hypertensive effects, anti-cancer cell proliferation activity and can induce cells apoptosis .

Tripartin	Histone Demethylase	Cancer
Tripartin is an inhibitor of histone demethylase. Tripartin inhibits the histone H3 lysine 9 demethylase KDM4 in HeLa cells .

U-14624	Dopamine β-hydroxylase	Neurological Disease
U-14624 is a potent and orally active dopamine beta-hydroxylase inhibitor. U-14624 suppresses the activities of aminopyrine N-demethylase, aniline hydroxylase and p-nitroanisole O-demethylase enzymes .

NCGC00247743 1 Publications Verification	Histone Demethylase	Cancer
NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

T-448	Histone Demethylase	Neurological Disease
T-448 is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀ of 22 nM. T-448 enhances H3K4 methylation in primary cultured rat neurons .

CBB1003 hydrochloride	Histone Demethylase	Cancer
CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003	Histone Demethylase	Cancer
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent *lysine-specific demethylase* 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

T-448 free base	Histone Demethylase	Neurological Disease
T-448 free base is a specific, orally active and irreversible inhibitor of lysine-specific demethylase 1 (LSD1, an H3K4 demethylase), with an IC₅₀ of 22 nM. T-448 free base enhances H3K4 methylation in primary cultured rat neurons .

SP2509 5+ Cited Publications	Histone Demethylase Apoptosis	Cancer
SP2509 is a potent and selective antagonist of *lysine specific demethylase* 1 (LSD1) with an IC₅₀** of 13 nM .

GSK-J1 10+ Cited Publications	Histone Demethylase	Cancer
GSK-J1 is a potent inhibitor of *H3K27me3/me2-demethylases* JMJD3/KDM6B and UTX/KDM6A, with IC₅₀** of 60 nM towards KDM6B.

S2157	Histone Demethylase Apoptosis	Cancer
S2157, a N-alkylated tranylcypromine (TCP) derivative, is a potent *lysine-specific demethylase* 1 (LSD1) inhibitor. S2157 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2157 induces apoptosis** in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2157 efficiently pass through the blood-brain barrier and can almost completely eradicate CNS leukemia in mice transplanted with T-ALL cells .

GSK 690	Histone Demethylase	Cancer
GSK 690 is a reversible inhibitor of lysine specific demethylase 1 (LSD1), with a K_d value of 9 nM and a biochemical IC₅₀ of 37 nM.

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

670 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 670 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L005

Epigenetics Compound Library

1,325 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1,325 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P2509

Histone H2A (1-20)	Peptides	Others
Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes .

HY-P1108A

Astressin 2B TFA	CFTR	Others
Astressin 2B TFA is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B TFA antagonizes CRF2-mediated inhibition of gastric emptying .

HY-P3066

SKF 100398 d(CH2)5Tyr(Et)VAVP	Vasopressin Receptor	Metabolic Disease
SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P4756

*N-(2-Carbamoyl-ethyl)-Val-Leu-anilide*	Peptides	Others
N-(2-Carbamoyl-ethyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P1108

Astressin 2B	CFTR	Others
Astressin 2B is a potent and selective corticotropin-releasing factor receptor 2 (CRF2) antagonist, with the IC₅₀ values of 1.3 nM and > 500 nM for CRF2 and CRF1, respectively. Astressin 2B antagonizes CRF2-mediated inhibition of gastric emptying .

HY-P2592

Ro 23-7014	Peptides	Others
Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

HY-P4521

*Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt*	MMP	Others
Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt is a MMP12 substrate, and can be used to detect MMP12 enzyme activity .

HY-P10563

Noraramtide BHV-1100	CD38	Cancer
Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .

Species:	Human (12) E.coli (1)
Tag:	His (8) SUMO (2) Tag Free (6) Myc (3) GST (2)
Source:	Sf9 insect cells (4) E. coli (11)

Cat. No.	Compare	Product Name	Species	Source

HY-P701887

	FTO Protein, Human FTO; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; m6A(m)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO	Human	E. coli
	FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human is the recombinant human-derived FTO protein, expressed by E. coli , with tag free. The total length of FTO Protein, Human is 474 a.a., .

HY-P702082

	KDM6B Protein, Human (Sf9) KDM6B; Lysine-specific demethylase 6B; JmjC domain-containing protein 3; Jumonji domain-containing protein 3; Lysine demethylase 6B; [histone H3]-trimethyl-L-lysine(27) demethylase 6B	Human	Sf9 insect cells
	KDM6B protein is a histone demethylase targeting "Lys-27" of histone H3, which mainly affects the histone code. Demethylates H3 "Lys-27" to shape the epigenetic landscape. KDM6B Protein, Human (Sf9) is the recombinant human-derived KDM6B protein, expressed by Sf9 insect cells , with tag free. The total length of KDM6B Protein, Human (Sf9) is 496 a.a., .

HY-P72165

	ERG11 Protein, Saccharomyces cerevisiae (GST) ERG11; CYP51; YHR007CLanosterol 14-alpha demethylase; EC 1.14.14.154; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; Sterol 14-alpha demethylase	Others	E. coli
	ERG11 Proteinas is a sterol 14α-demethylase, a key enzyme in the ergosterol biosynthetic pathway, particularly in the late pathway that occurs in the endoplasmic reticulum membrane. ERG11 catalyzes the three-step removal of the 14α-methyl group from lanosterol, releasing it as a formate, resulting in the conversion of the sterol into a key intermediate in ergosterol biosynthesis. ERG11 Protein, Saccharomyces cerevisiae (GST) is the recombinant ERG11 protein, expressed by E. coli , with N-GST labeled tag. The total length of ERG11 Protein, Saccharomyces cerevisiae (GST) is 20 a.a., with molecular weight of ~29.1 kDa.

HY-P701888

	FTO Protein, Human (His) FTO; Alpha-ketoglutarate-dependent dioxygenase FTO; Fat mass and obesity-associated protein; U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO; mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO; m6A(m)-demethylase FTO; mRNA N(6)-methyladenosine demethylase FTO; tRNA N1-methyl adenine demethylase FTO	Human	E. coli
	FTO protein is an RNA demethylase that regulates fat mass, lipogenesis, and energy homeostasis by targeting N(6)-methyladenosine in mRNA. It also demethylates m6A in U6 snRNA and m6A(m) in 5'-cap, affecting mRNA stability. FTO Protein, Human (His) is the recombinant human-derived FTO protein, expressed by E. coli , with N-6*His labeled tag. The total length of FTO Protein, Human (His) is 474 a.a., .

HY-P701616

	PHF8 Protein, Human PHF8; Histone lysine demethylase PHF8; PHD finger protein 8; [histone H3]-dimethyl-L-lysine(36) demethylase PHF8; [histone H3]-dimethyl-L-lysine(9) demethylase PHF8	Human	E. coli
	The PHF8 protein is a histone lysine demethylase that plays a key role in cell cycle progression, rDNA transcription, and brain development. It selectively demethylates H3 'Lys-9' (H3K9Me1 and H3K9Me2), H3 'Lys-27' (H3K27Me2) and H4 'Lys-20' (H4K20Me1). PHF8 Protein, Human is the recombinant human-derived PHF8 protein, expressed by E. coli , with tag free. The total length of PHF8 Protein, Human is 446 a.a., .

HY-P701617

	PHF8 Protein, Human (His) PHF8; Histone lysine demethylase PHF8; PHD finger protein 8; [histone H3]-dimethyl-L-lysine(36) demethylase PHF8; [histone H3]-dimethyl-L-lysine(9) demethylase PHF8	Human	E. coli
	The PHF8 protein is a histone lysine demethylase that plays a key role in cell cycle progression, rDNA transcription, and brain development. It selectively demethylates H3 'Lys-9' (H3K9Me1 and H3K9Me2), H3 'Lys-27' (H3K27Me2) and H4 'Lys-20' (H4K20Me1). PHF8 Protein, Human (His) is the recombinant human-derived PHF8 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PHF8 Protein, Human (His) is 446 a.a., .

HY-P702083

	KDM6B Protein, Human (Sf9, His) KDM6B; Lysine-specific demethylase 6B; JmjC domain-containing protein 3; Jumonji domain-containing protein 3; Lysine demethylase 6B; [histone H3]-trimethyl-L-lysine(27) demethylase 6B	Human	Sf9 insect cells
	KDM6B protein is a histone demethylase targeting "Lys-27" of histone H3, which mainly affects the histone code. Demethylates H3 "Lys-27" to shape the epigenetic landscape. KDM6B Protein, Human (Sf9, His) is the recombinant human-derived KDM6B protein, expressed by Sf9 insect cells , with N-8*His labeled tag. The total length of KDM6B Protein, Human (Sf9, His) is 496 a.a., .

HY-P701618

	JMJD2A Protein, Human KDM4A; Lysine-specific demethylase 4A; JmjC domain-containing histone demethylation protein 3A; Jumonji domain-containing protein 2A; [histone H3]-trimethyl-L-lysine(36) demethylase 4A; [histone H3]-trimethyl-L-lysine(9) demethylase 4A	Human	E. coli
	The JMJD2A protein is a central histone demethylase in the histone code that specifically targets "Lys-9" and "Lys-36" of histone H3. It excludes demethylation of H3 "Lys-4", "Lys-27" and H4 "Lys-20". JMJD2A Protein, Human is the recombinant human-derived JMJD2A protein, expressed by E. coli , with tag free. The total length of JMJD2A Protein, Human is 359 a.a., .

HY-P701620

	JMJD2D Protein, Human KDM4D; Lysine-specific demethylase 4D; JmjC domain-containing histone demethylation protein 3D; Jumonji domain-containing protein 2D; [histone H3]-trimethyl-L-lysine(9) demethylase 4D	Human	E. coli
	The JMJD2D protein is a core histone demethylase in the complex histone code, specifically targeting "Lys-9" of histone H3. Importantly, it does not demethylate H3 "Lys-4", "Lys-27", "Lys-36" or H4 "Lys-20". JMJD2D Protein, Human is the recombinant human-derived JMJD2D protein, expressed by E. coli , with tag free. The total length of JMJD2D Protein, Human is 522 a.a., .

HY-P72049

	CYP51 Protein, Mycobacterium tuberculosis (Baculovirus, His-Myc) cyp51; MT0788Lanosterol 14-alpha demethylase; EC 1.14.14.154; CYPLI; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; Sterol 14-alpha demethylase	Others	Sf9 insect cells
	CYP51 Proteinas is a sterol 14α-demethylase that acts with an unknown physiological substrate and accepts electrons from the iron-sulfur ferredoxin Fdx. In vitro, it catalyzes the C14-demethylation of lanosterol, 24,25-dihydrolanosterol, and obtanyol, showing stereoselectivity in producing 8,14-diene. CYP51 Protein, Mycobacterium tuberculosis (Baculovirus, His-Myc) is the recombinant CYP51 protein, expressed by Sf9 insect cells , with N-10*His, C-Myc labeled tag. The total length of CYP51 Protein, Mycobacterium tuberculosis (Baculovirus, His-Myc) is 451 a.a., with molecular weight of ~54.8 kDa.

HY-P75551

	LSD1 Protein, Human (sf9, His-GST) Lysine-specific histone demethylase 1A; KDM1A; AOF2; KDM1; KIAA0601; LSD1	Human	Sf9 insect cells
	The LSD1 protein is a histone demethylase that modifies histone H3 by demethylating “Lys-4” (H3K4me) and “Lys-9” (H3K9me).It acts as a coactivator or corepressor, oxidizing substrates via FAD to generate imines that are subsequently hydrolyzed.LSD1 Protein, Human (sf9, His-GST) is the recombinant human-derived LSD1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P701621

	KDM2A Protein, Human KDM2A; Lysine-specific demethylase 2A; CXXC-type zinc finger protein 8; F-box and leucine-rich repeat protein 11; F-box protein FBL7; F-box protein Lilina; F-box/LRR-repeat protein 11; JmjC domain-containing histone demethylation protein 1A; [Histone-H3]-lysine-36 demethylase 1A	Human	E. coli
	The KDM2A protein is a histone demethylase targeting "Lys-36" of histone H3. It plays a key role in the histone code, especially the demethylation of dimethylated H3 "Lys-36". Methylation. In addition to histone demethylation, KDM2A also recognizes and binds phosphorylated proteins, promoting their ubiquitination and degradation. KDM2A Protein, Human is the recombinant human-derived KDM2A protein, expressed by E. coli , with tag free. The total length of KDM2A Protein, Human is 115 a.a., .

HY-P701622

	KDM2A Protein, Human (His) KDM2A; Lysine-specific demethylase 2A; CXXC-type zinc finger protein 8; F-box and leucine-rich repeat protein 11; F-box protein FBL7; F-box protein Lilina; F-box/LRR-repeat protein 11; JmjC domain-containing histone demethylation protein 1A; [Histone-H3]-lysine-36 demethylase 1A	Human	E. coli
	The KDM2A protein is a histone demethylase targeting "Lys-36" of histone H3. It plays a key role in the histone code, especially the demethylation of dimethylated H3 "Lys-36". Methylation. In addition to histone demethylation, KDM2A also recognizes and binds phosphorylated proteins, promoting their ubiquitination and degradation. KDM2A Protein, Human (His) is the recombinant human-derived KDM2A protein, expressed by E. coli , with N-6*His labeled tag. The total length of KDM2A Protein, Human (His) is 115 a.a., .

HY-P71479

	AlkB Protein, E.coli (Myc, His-SUMO) alkB; aidD; b2212; JW2200Alpha-ketoglutarate-dependent dioxygenase AlkB; EC 1.14.11.33; Alkylated DNA repair protein AlkB; DNA oxidative demethylase AlkB	E.coli	E. coli
	AlkB Protein, E.coli (Myc, His-SUMO) is a protein found in E. coli, plays a major role in oxidative dealkylation processes.

HY-P71585

	KDM3B Protein, Human (Myc, His-SUMO) 5qNCA; C5orf7; JHDM2B; JmjC domain containing histone demethylation protein 2B; JmjC domain-containing histone demethylation protein 2B; jmjd1b; Jumonji domain containing 1B; Jumonji domain containing protein 1B; Jumonji domain-containing protein 1B; KDM3B; KDM3B_HUMAN; KIAA1082; Lysine (K) specific demethylase 3B ; Lysine-specific demethylase 3B; NET22; Nuclear protein 5qNCA	Human	E. coli
	KDM3B protein is a histone demethylase that mainly targets "Lys-9" of histone H3, catalyzes demethylation and produces formaldehyde and succinic acid by-products. In addition to histone modifications, KDM3B has been implicated in tumor suppressor activity, indicating its importance in cellular processes, gene expression regulation, and epigenetic modifications. KDM3B Protein, Human (Myc, His-SUMO) is the recombinant human-derived KDM3B protein, expressed by E. coli , with C-Myc, N-SUMO, N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17514S

Itraconazole-d5

Itraconazole-d₅ is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

HY-113038AS

α-Hydroxyglutaric acid-13C5 disodium

α-Hydroxyglutaric acid- ¹³C₅ (sodium) is the ¹³C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-113038AS1

α-Hydroxyglutaric acid-d4 disodium

α-Hydroxyglutaric acid-d₄ (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-17514S2

Itraconazole-d9

Itraconazole-d₉ is the deuterium labeled Itraconazole[1]. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor[2][3][4][5].

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83693

	ALKBH5 Antibody (YA3429) ABH5,AlkB,OFOXD,OFOXD1,RNA demethylase ALKBH5 antibody	WB, IHC-P	Human, Mouse, Rat
	ALKBH5 Antibody is an unconjugated, approximately 44 kDa, rabbit-derived, anti-ALKBH5 monoclonal antibody. ALKBH5 Antibody can be used for: WB/IHC-P expriments in human,mouse,rat background without labeling.

HY-P80731

	KDM1A Antibody (YA718) KDM1A; AOF2; KDM1; KIAA0601; LSD1; Lysine-specific histone demethylase 1A; BRAF35-HDAC complex protein BHC110; Flavin-containing amine oxidase domain-containing protein 2	WB	Human, Mouse, Monkey
	KDM1A Antibody (YA718) is a non-conjugated and Mouse origined monoclonal antibody about 93 kDa, targeting to KDM1A (1B2). It can be used for WB assays with tag free, in the background of Human, Mouse, Monkey.

HY-P82534

	MBD2 Antibody (YA2279) demethylase; DMTase; Mbd2; MBD2a	WB, IHC-P, ICC/IF	Human
	MBD2 Antibody (YA2279) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2279), targeting MBD2, with a predicted molecular weight of 43 kDa (observed band size: 43/32/29 kDa). MBD2 Antibody (YA2279) can be used for WB, IHC-P, ICC/IF experiment in human background.

HY-P83638

	KDM1B Antibody (YA3383) AOF1; KDM1B; LSD2; Lysine-specific histone demethylase 1B; Lysine-specific histone demethylase 2	WB, ICC/IF, IP, FC	Human, Mouse, Rat
	KDM1B Antibody (YA3383) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3383), targeting KDM1B, with a predicted molecular weight of 92 kDa (observed band size: 92 kDa). KDM1B Antibody (YA3383) can be used for WB, ICC/IF, IP, FC experiment in human, mouse, rat background.

HY-P83497

	Mint3 Antibody (YA3242) Histone lysine demethylase MINA; MDIG; MINA; NO52; ROX	WB, ICC/IF	Human, Mouse
	Mint3 Antibody (YA3242) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3242), targeting Mint3, with a predicted molecular weight of 53 kDa (observed band size: 53 kDa). Mint3 Antibody (YA3242) can be used for WB, ICC/IF experiment in human, mouse background.

HY-P81319

	JMJD6 Antibody (YA1064) JMJD6; KIAA0585; PTDSR; Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6; Histone arginine demethylase JMJD6; JmjC domain-containing protein 6; Jumonji domain-containing protein 6; Lysyl-hydroxylase JMJD6; Peptide-lysine 5-diox	WB, ICC/IF	Human
	JMJD6 Antibody (YA1064) is a mouse-derived non-conjugated IgG1 antibody (Clone NO.: YA1064), targeting JMJD6, with a predicted molecular weight of 46 kDa (observed band size: 62 kDa). JMJD6 Antibody (YA1064) can be used for WB, ICC/IF experiment in human background.

HY-P82579

	PHF8 Antibody (YA2324) Histone lysine demethylase PHF8; MRXSSD; PHD finger protein 8; PHF8; ZNF422	WB, ICC/IF, IP	Human, Mouse, Rat
	PHF8 Antibody (YA2324) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2324), targeting PHF8, with a predicted molecular weight of 118 kDa (observed band size: 140 kDa). PHF8 Antibody (YA2324) can be used for WB, ICC/IF, IP experiment in human, mouse, rat background.

HY-P82791

	KDM4B Antibody (YA2536) KDM4B; JHDM3B; JMJD2B; KIAA0876; Lysine-specific demethylase 4B; JmjC domain-containing histone demethylation protein 3B; Jumonji domain-containing protein 2B	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat
	KDM4B Antibody (YA2536) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2536), targeting KDM4B, with a predicted molecular weight of 122 kDa (observed band size: 150 kDa). KDM4B Antibody (YA2536) can be used for WB, IHC-P, ICC/IF, FC experiment in human, mouse, rat background.

HY-P83586

	KDM4A Antibody (YA3331) KDM4A; JHDM3A; JMJD2; JMJD2A; KIAA0677; Lysine-specific demethylase 4A; JmjC domain-containing histone demethylation protein 3A; Jumonji domain-containing protein 2A	WB, IP	Human
	KDM4A Antibody (YA3331) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3331), targeting KDM4A, with a predicted molecular weight of 121 kDa (observed band size: 150 kDa). KDM4A Antibody (YA3331) can be used for WB, IP experiment in human background.